104 results about "Cellular Autophagy" patented technology

The invention provides a polypeptide polymer nanomaterial and a preparing method and application thereof. The polypeptide polymer nanomaterial comprises chitosan, a polypeptide sequence for recognizing beta-amyloid protein and a polypeptide sequence for activating autophagy, and the polypeptide sequences are connected to the chitosan. A polypeptide polymer prepared through solid-phase synthesis and Michael addition has good biological compatibility and anti-A[beta] neurotoxicity, polypeptide polymer nanospheres obtained from the polypeptide polymer can be co-assembled with A[beta] so as to effectively prevent aggregation of A[beta] and reduce the neurotoxicity of A[beta], meanwhile, a co-assembly can activate autophagy after entering cells, A[beta] can be degraded through autophagy, so that Alzheimer's disease can be treated in a synergic mode, the Alzheimer's disease treatment efficiency of the polypeptide nanomaterial is improved greatly, and application prospects are broad.

The invention belongs to the technical field of biology and relates to a drug composition reducing in-vivo and in-vitro toxicity of a nano drug delivery material and a preparation method thereof. In the invention, biological technologies are employed for reducing the in-vivo and in-vitro toxicity of the nano drug delivery material and the in-vivo and in-vitro toxicity of an autophagy-intervention nano material are controlled through the biological technologies, thereby reducing adverse side effects of the nano materials and improve safety of application of the nano materials. The invention particularly provides an autophagy-intervention composition which is composed of following substances including, but not limited to an autophagy-intervention drug (such as a compound or a polypeptide), an autophagy-related gene, an autophagy-related signal pathway protein blocking agent, with the nano material.

The invention belongs to the field of biological pharmacy, and relates to a screening method for screening candidate combination molecules through cell death caused by combination of a tumor cell autophagy inducer and a micro-molecular compound, screened compound molecules may not have antitumor activity, and have the antitumor activity after the screened compound molecules are combined with the cell autophagy inducer, such as an HDAC inhibitor, so a drug combination scheme can be determined. In the invention, cancer cells cultured in vitro are respectively processed by the tumor cell autophagy inductor and single compounds as an object, the degree of the cultured cell death caused by the compounds and the cell autophagy inducer is determined, and cell autophagy-based antitumor drugs are screened. A result of cell experiments proves that the method can be used to screen the combination drugs in order to prepare antitumor medicine compositions of the HDAC inhibitor and the micro-molecular compound, and the medicinal compositions are suitable for all dosage forms.

The invention relates to the technical field of medicines and biology, and concretely relates to a pharmaceutical composition treating tumors. The pharmaceutical composition consists of one or a plurality of autophagy adjusting medicines and a monoclonal antibody medicine. The autophagy adjusting medicine(s) and the monoclonal antibody medicine in the pharmaceutical composition are administrated in a combined administration manner or in a sequential administration manner. By adjusting cell autophagy, the curative effect of the monoclonal antibody medicine on various tumors is enhanced. By utilizing the cell autophagy adjusting medicines to activate / inhibit autophagy, the curative effects of a plurality of monoclonal antibody medicines on lymphoma, stomach cancer, breast cancer, lung cancer, ovarian cancer and brain tumor are enhanced, and especially the curative effects on lymphoma, stomach cancer and breast cancer are enhanced.

The invention discloses a PICT-1 (protein interacting with carboxyl terminus 1) protein truncated mutant which has a sequence represented by sites from 181 to 478 in SEQ ID NO: 1. Due to the overexpression of the truncated mutant, the UBF activity can be adjusted, rDNA transcription can be suppressed, and cell autophage can be caused; the PICT-1 protein truncated mutant can be used for preparing an anti-tumor medicament, particularly a medicament for treating glioma. The invention further discloses a nucleic acid for encoding the truncated mutant and application of the nucleic acid, an expression vector of the nucleic acid for encoding the truncated mutant, a host cell comprising the expression vector, and a method and a device for treating the glioma.

The invention provides a pharmaceutical composition for mild photothermal therapy of tumors as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is composed of a dual-targeting amphiphilic glucan derivative carrier, a material (PTA) with photo-thermal conversion performance and an autophagy inhibitor. The dual-targeting amphiphilic glucan derivative carrier can be self-assembled in water to form nano-micelles, and is physically loaded with PTA and an autophagy inhibitor for tumor photothermal therapy. The preparation is mainly characterized in that: 1) the preparation has active dual-targeting capability of tumor cells and tumor-related fibroblasts, and can efficiently enter the cells through the action of receptor ligands, so that the transfer efficiency of the preparation is improved; 2) under the irradiation of 808nm laser, PTA absorbs light energy and efficiently converts the light energy into heat, and the autophagy inhibitor inhibits the autophagy behavior of tumor cells and sensibilizes photo-thermal, so that an excellent mild photo-thermal treatment effect is realized, and the physical barrier of a tumor matrix can be weakened; tumor photothermal can further induce tumor cells to generate immunogenic cell death, generated tumor fragments can further activate an immune system, and the tumor photothermal treatment effect is greatly improved.

The invention discloses a two-photon pH (potential of hydrogen) ratio measurement fluorescence probe for monitoring cell autophagy, a preparation method of the fluorescence probe and an application. The structure of the two-photon pH (potential of hydrogen) ratio measurement fluorescence probe for monitoring cell autophagy is as shown in the specification. The fluorescence probe has specific fluorescence signal response to pH. By the aid of a cell co-localization test, the fluorescence probe can be specifically targeted to cell lysosomes, a cell toxicity test indicates that the fluorescence probe has almost no toxic and side effect on cells, a two-photon confocal fluorescence micro-imaging test indicates that the fluorescence probe has good penetrability for MCF-7 cells, pKa of the fluorescence probe is 3.88 through calculation, the fluorescence probe is suitable for monitoring change ranges of the pH of the cell lysosomes, and the cell autophagy process can be monitored in real time by detecting change of the pH of the cell lysosomes.

The invention relates to an autophagic inhibiting polypeptide which has an amino acid sequence of LPDISLKDLQFLQSFCPSEVQ. The polypeptide can be prepared by an artificial synthesis or host cell expression method, and can be used for preparing tumor treatment medicines. The autophagic inhibiting polypeptde only has 21 amino acids, can be easily and feasibly prepared by either artificially synthesizing or applying host cell expression, and is beneficial to large-scale popularization and utilization. The polypeptide is derived from inherent protein in a living body, cannot cause immune elimination in an animal experiment, has small toxicity to cells, and is more specific. The inhibiting polypeptide can be used for introducing a gene segment coding the polypeptide into a cell for stable expression through a lentivirus or transfection and other means, is convenient to operate, and is beneficial to researches for cell level and animal level.

The present invention relates to the technical field of biomedicine. According to the present invention, research results show that arginase can significantly induce head and neck neoplasm cells to produce autophagy while the autophagy can partially counteract the anti-tumor effect of the arginase; and with use of the autophagy inhibitor to inhibit the autophagy, and the sensitivity of the head and neck neoplasm cells on the arginase can be increased so as to enhance the treatment effect of the arginase on the head and neck neoplasms. The present invention provides a preparation for combined treatment of head and neck neoplasms, specifically a drug composition comprising the autophagy inhibitor and the arginase. The present invention further provides applications of the drug composition in preparation of drugs for treatment of head and neck neoplasms, especially laryngeal cancer, hypopharyngeal cancer and nasopharyngeal cancer.